These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 17014009)
1. Magnetic resonance imaging in rheumatologic practice: low field or standard. Sharp JT J Rheumatol; 2006 Oct; 33(10):1925-7. PubMed ID: 17014009 [No Abstract] [Full Text] [Related]
2. Magnetic resonance imaging is more sensitive than radiographs in detecting change in size of erosions in rheumatoid arthritis. Chen TS; Crues JV; Ali M; Troum OM J Rheumatol; 2006 Oct; 33(10):1957-67. PubMed ID: 16881098 [TBL] [Abstract][Full Text] [Related]
3. Biomarkers in rheumatologic disease: a review. Whitt I; Reed A Minn Med; 2009 Sep; 92(9):38-41. PubMed ID: 19877477 [TBL] [Abstract][Full Text] [Related]
4. [10 years of treatment with TNF inhibitors--are we on the safe side?]. Zink A; Schneider M Z Rheumatol; 2010 Nov; 69(9):772-3. PubMed ID: 21063824 [No Abstract] [Full Text] [Related]
5. The use of methotrexate in childhood rheumatic diseases. Wallace CA Arthritis Rheum; 1998 Mar; 41(3):381-91. PubMed ID: 9506564 [No Abstract] [Full Text] [Related]
6. [Do DMARDs contibute to impaired healing after surgery? Should they be discontinued before surgery?]. Glück T; Müller-Ladner U Dtsch Med Wochenschr; 2007 Sep; 132(37):1901-4. PubMed ID: 17823884 [No Abstract] [Full Text] [Related]
7. Dissemination and evaluation of the 3E initiative recommendations for use of methotrexate in rheumatic disorders: results of a study among 2233 rheumatologists. Gossec L; Bijlsma JW; Bombardier C; Canhão H; Devlin J; Edwards CJ; Hamuryudan V; Kvien TK; Leeb BF; Martín-Mola EM; Mielants H; Müller-Ladner U; Ostergaard M; Pereira IA; Ramos-Remus C; Zochling J; Dougados M Ann Rheum Dis; 2011 Feb; 70(2):388-9. PubMed ID: 20472594 [No Abstract] [Full Text] [Related]
8. An update on methotrexate. Braun J; Rau R Curr Opin Rheumatol; 2009 May; 21(3):216-23. PubMed ID: 19373092 [TBL] [Abstract][Full Text] [Related]
10. Is there a rationale for switching from one anti-tumor necrosis factor agent to another? Haraoui B J Rheumatol; 2004 Jun; 31(6):1021-2. PubMed ID: 15170907 [No Abstract] [Full Text] [Related]
11. More evidence of declining incidence of amyloidosis associated with inflammatory rheumatic diseases. Vasala M; Immonen K; Kautiainen H; Hakala M Scand J Rheumatol; 2010 Nov; 39(6):461-5. PubMed ID: 20560815 [TBL] [Abstract][Full Text] [Related]
12. Toward a better understanding of methotrexate. Kremer JM Arthritis Rheum; 2004 May; 50(5):1370-82. PubMed ID: 15146406 [No Abstract] [Full Text] [Related]
13. Introduction to special section: biologic agents in the treatment of rheumatic diseases-the first decade. Yelin E; Katz P Arthritis Rheum; 2009 May; 61(5):559. PubMed ID: 19405010 [No Abstract] [Full Text] [Related]
15. [The use of methotrexate in rheumatology: results and prospects]. Nasonov EL Klin Med (Mosk); 1996; 74(5):10-5. PubMed ID: 8999172 [No Abstract] [Full Text] [Related]